Articles related to CHECKPOINT INHIBITORS

This one-credit activity features an expert panel providing their perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.

This comprehensive review highlights the history of discovering RAS and the decades of studies targeting KRAS-driven lung cancer, to the present applications. Although KRAS inhibitors have 36%–45% objective response rates with a median duration of response of 10 months, many tumors do not respond, and a variety of mechanisms of resistance have been observed, including new KRAS alterations, activation of alternate RTK pathway proteins, bypass pathways, and transcriptional remodeling. The authors conclude with a discussion of ongoing clinical trials aimed at overcoming resistance to KRAS inhibitors.

In this interview, Nicole Lamanna, MD, discusses challenges and application of BTK inhibitors, results with pirtobrutinib in hematologic malignancies, specifically addressing CLL, and shares her personal observations regarding pirtobrutinib use.

Despite the array of intensive treatment approaches, local control and overall survival rates in patients with advanced-stage disease remain low (approximately 40%–50% at 5 years). This review discusses recent studies integrating ICIs into definitive treatment regimens.

The authors summarize the results of the major studies of ICB monotherapy and combinations; review novel combinations under investigation, including ICB with cellular therapies; and discuss potential candidate biomarkers for improving the selection of patients who may respond to ICB.

When tested in mice with pancreatic cancer, a BET inhibitor/anti-PD-1 combination prevented neoplastic transformation induced by the oncogene KRAS, increased survival and increased the recruitment of cytotoxic T-cells to the tumor.